Vanguard Group Inc. reduced its stake in shares of Allergan PLC. (NYSE:AGN) by 7.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,353,469 shares of the company’s stock after selling 1,689,478 shares during the period. Vanguard Group Inc.’s holdings in Allergan PLC. were worth $5,340,691,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Veritas Asset Management LLP acquired a new stake in Allergan PLC. during the first quarter valued at about $761,339,000. Iridian Asset Management LLC CT raised its stake in Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares in the last quarter. First Manhattan Co. raised its stake in Allergan PLC. by 193.3% in the first quarter. First Manhattan Co. now owns 497,793 shares of the company’s stock valued at $114,646,000 after buying an additional 328,062 shares in the last quarter. Schroder Investment Management Group raised its stake in Allergan PLC. by 133.3% in the first quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock valued at $100,225,000 after buying an additional 238,796 shares in the last quarter. Finally, Swiss National Bank increased its position in Allergan PLC. by 20.5% in the first quarter. Swiss National Bank now owns 1,329,086 shares of the company’s stock valued at $317,545,000 after buying an additional 226,200 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.
Allergan PLC. (NYSE AGN) traded down 0.35% on Friday, hitting $223.99. 2,006,235 shares of the stock were exchanged. The firm has a market cap of $74.88 billion, a P/E ratio of 6.82 and a beta of 1.16. The company has a 50-day moving average of $243.31 and a 200 day moving average of $238.68. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $3.35 EPS. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. Allergan PLC.’s payout ratio is 9.95%.
TRADEMARK VIOLATION NOTICE: This story was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/allergan-plc-nyseagn-shares-sold-by-vanguard-group-inc-updated-updated-updated.html.
Several equities analysts have recently commented on AGN shares. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Monday, June 12th. Mizuho decreased their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. UBS AG reaffirmed a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Citigroup Inc. increased their price target on Allergan PLC. to $261.00 and gave the stock a “buy” rating in a research report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $275.49.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.